E
Elios Biotechnology (Shanghai)
Filtration-based separation and purification solutions for pharmaceuticals
About Elios Biotechnology (Shanghai)
Alioth Biotech, founded in Shanghai in 2021 by Jia Qijun, develops and manufactures filtration-based products for pharmaceutical processing. The company aims to provide high-quality separation and purification solutions that comply with both domestic and international regulations. Alioth serves pharmaceutical manufacturers by helping them meet regulatory standards, improve production safety, and optimize their bioprocess workflows.
The company operates with a global footprint, featuring R&D centers in Boston, USA, and Shanghai, China, alongside production facilities in Shanghai and Hangzhou. This international structure is led by a team with extensive experience in membrane and filtration technology, focusing on securing the supply chain and enhancing drug manufacturing safety for pharmaceutical companies worldwide. The leadership team, including founder and CEO Jia Qijun, possesses over a decade of management experience from leading multinational life science enterprises.
Since its inception, Alioth has secured several hundred million yuan through multiple funding rounds. Notable financing includes a Series A round in October 2022 from Matrix Partners China and Legend Capital, a Series A+ round in October 2023 led by the AstraZeneca-CICC Fund, and a Series A++ round in September 2025 that raised over RMB 100 million, led by Lapam Capital. These funds are directed towards the R&D of filtration membrane materials and the commercialization of its filter products. The company's product portfolio includes cartridge filters, capsule filters, depth filters, and filtration hardware systems, catering to applications like blood products, vaccines, and monoclonal antibodies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $14M | $55M | Longpan Investment · Guohai Innovation Capital | ↗ |
| SERIES A✓Equity / VC | Oct 2023 | $14M | $55M | AstraZeneca Pharmaceutical · Yi Shuishuishan · Legend Capital · Matrix Partners China | ↗ |
Growth signals
Latest recorded traffic for Elios Biotechnology (Shanghai) is 1.5K monthly website visits, up 78.6% over the last three months. Elios Biotechnology (Shanghai)'s team grew 21.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Elios Biotechnology (Shanghai) in the Jing'an District ecosystem
The Elios Biotechnology (Shanghai) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Legend Capital
Matrix Partners China
AstraZeneca Pharmaceutical- YSYi Shuishuishan
- LILongpan Investment
- GCGuohai Innovation Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elios Biotechnology (Shanghai) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elios Biotechnology (Shanghai)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








